Heart failure & cardiomyopathies
Contemporary clinical characteristics and management patterns in hypertrophic cardiomyopathy: insights from baseline enrolment data in a nationwide prospective Japanese registry
Authors' conclusion
As the first large-scale, prospective HCM registry in Japan, this study provides valuable baseline data on the clinical characteristics and management of HCM. These findings will help address gaps between current practice and guideline recommendations, improving the care of patients with HCM.
Study context
- Population
- Patients with hypertrophic cardiomyopathy (HCM) enrolled at referral hospitals across Japan starting in 2016patients enrolled by December 2019
- Participants
- 1,485 patients
- Outcome
- Age
- Follow-up
- At registration and diagnosis
Methodological detailsconsecutive patients, 24 referral hospitals across Japan, baseline enrolment data
- Consecutive patients
- 24 referral hospitals across Japan
- Baseline enrolment data
Main finding
As reported in the abstract
Median age at registration
69 years
Median age at diagnosis
60 years
Men
54%
Observational data: associations, not effects.
Further findings
Class IIa primary-prevention defibrillator recommendation in the whole cohort, and defibrillator implantation among class IIa patients, by guideline · at registration
Class IIa recommendation, whole cohort
Defibrillator implantation in class IIa
Familial HCM
- Familial HCM confirmed
- 18%
HCM phenotypes
- Hypertrophic obstructive cardiomyopathy (HOCM)
- 36%
- Mid-ventricular obstruction
- 8%
- Apical HCM
- 14%
- End-stage phase
- 4%
Atrial fibrillation · at registration
- Atrial fibrillation
- 27%
- Majority asymptomatic or with mild symptoms at registration
Prior adverse outcomes
- Prior sustained ventricular tachycardia or fibrillation
- 6%
- Heart failure requiring hospitalisation
- 11%
- Embolic events
- 5%
Defibrillator implantation
- Defibrillator implantation
- 11%
Management of patients with HOCM
- Beta blockers, of patients with HOCM
- 90%
- Cibenzoline, of patients with HOCM
- 51%
- Septal reduction therapies, of patients with HOCM
- 22%
- Surgical myectomy, of patients with HOCM
- 6%
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →